10.715  0.185 (1.76%)		04-29 13:58
Open: 10.57 High: 10.74 Volume: 178,389		Pre. Close: 10.53 Low: 10.47 Market Cap: 379(M)

Short term
Mid term
Targets	6-month :	14.3	1-year :	16.02
Resists	First :	12.24	Second :	13.72
Pivot price	11.47
Supports	First :	9.86	Second :	8.21
MAs	MA(5) :	10.35	MA(20) :	11.87
	MA(100) :	10.83	MA(250) :	14.57
MACD	MACD :	-0.5	Signal :	-0.2
%K %D	K(14,3) :	14.3	D(3) :	9.1
RSI	RSI(14): 41.1
52-week	High :	28.25	Low :	7.59

Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.
[ HROW ] has closed above bottom band by 32.2%. Bollinger Bands are 105.2% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 6 days. This is a sign that the current trend might continue.

If tomorrow:	Open lower	Open higher
High:	10.72 - 10.78	10.78 - 10.84
Low:	9.91 - 9.99	9.99 - 10.06
Close:	10.41 - 10.53	10.53 - 10.63

Harrow Health, Inc. operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business; and DEXYCU for the treatment of post-operative inflammation. The company also holds equity interests in Surface Ophthalmics, Inc., a clinical-stage pharmaceutical company that focuses on development and commercialization of therapeutics for ocular surface diseases; Melt Pharmaceuticals, Inc., a clinical-stage pharmaceutical company that focused on the development and commercialization of proprietary non-intravenous, sedation, and anesthesia therapeutics for human medical procedures in hospital, outpatient, and in-office settings; and Eton Pharmaceuticals, Inc., a commercial-stage pharmaceutical company that engages in developing and commercializing drug products. Harrow Health, Inc. owns royalty rights in four clinical stage drug candidates being developed by Surface Ophthalmics, Inc. and Melt Pharmaceuticals, Inc. The company was formerly known as Imprimis Pharmaceuticals, Inc. and changed its name to Harrow Health, Inc. in December 2018. Harrow Health, Inc. was incorporated in 2006 and is headquartered in San Diego, California.

Thu, 25 Apr 2024
Harrow Health, Inc. (NASDAQ:HROW) Major Shareholder Opaleye Management Inc. Purchases 11,715 Shares - MarketBeat

Thu, 25 Apr 2024
Insider Buying: Harrow Health, Inc. (NASDAQ:HROW) Major Shareholder Buys 20,000 Shares of Stock - MarketBeat

Mon, 25 Mar 2024
Harrow Inc (HROW) Stock: What Does the Chart Say Monday? - InvestorsObserver

Tue, 19 Mar 2024
Harrow Health Inc Unveils Investor Presentation Update - TipRanks.com - TipRanks

Wed, 13 Mar 2024
Harrow (HROW) Fell on Lowering the Guidance - Yahoo Finance

Wed, 03 Jan 2024
Harrow Inc. uses tech partnerships to distribute Vevye eyedrops - Nashville Business Journal - The Business Journals

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Outperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Outperform
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Underperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Underperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Outperform

Exchange: NASDAQ
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Shares Out	35 (M)
Shares Float	27 (M)
Held by Insiders	14.5 (%)
Held by Institutions	66.6 (%)
Shares Short	6,120 (K)
Shares Short P.Month	5,490 (K)

EPS	-0.75
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	2
Profit Margin	-18.8 %
Operating Margin	-12.4 %
Return on Assets (ttm)	0.2 %
Return on Equity (ttm)	-50 %
Qtrly Rev. Growth	78.8 %
Gross Profit (p.s.)	0
Sales Per Share	3.68
EBITDA (p.s.)	0.33
Qtrly Earnings Growth	0 %
Operating Cash Flow	4 (M)
Levered Free Cash Flow	-141 (M)

PE Ratio	-14.22
PEG Ratio	-2.3
Price to Book value	5.3
Price to Sales	2.89
Price to Cash Flow	98.16

Dividend	0
Forward Dividend	0
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.